Promising Phase II Trial Results for Iruplinalkib Tablets Unveiled
![Promising Phase II Trial Results for Iruplinalkib Tablets Unveiled](https://investorshangout.com/images/blog/ihnews-Promising%20Phase%20II%20Trial%20Results%20for%20Iruplinalkib%20Tablets%20Unveiled.jpg)
Phase II Clinical Trial Overview
During a recent global health conference, remarkable findings were shared regarding the Phase II clinical trial of iruplinalkib tablets, also recognized as Qixinke. This trial, referred to as the INTELLECT study, delved into the effects of the drug on patients battling anaplastic lymphoma kinase (ALK)-positive crizotinib-resistant non-small-cell lung cancer (NSCLC).
Understanding Iruplinalkib
Iruplinalkib, developed by Qilu Pharmaceutical, is an advanced ALK/ROS1 kinase inhibitor. It garnered approval in June 2023 from the NMPA for treating patients with ALK-positive locally advanced or metastatic NSCLC who demonstrated progress after crizotinib therapy or were unable to endure its side effects. Earlier this year, it also received approval for first-line treatment for ALK-positive NSCLC.
Study Leadership and Results
The study, spearheaded by Prof. Yuankai Shi from the Cancer Hospital of the Chinese Academy of Medical Sciences & Peking Union Medical College, has made significant strides. The preliminary data was initially published in BMC Medicine in 2023, presenting its findings after an extended two-year follow-up at the conference.
Trial Participants and Survival Rates
The INTELLECT study involved 146 participants, providing comprehensive insights into treatment efficacy. As of the last follow-up, participants had a median follow-up duration of 42.41 months, showcasing a median overall survival (OS) rate of 41.79 months. Furthermore, the trial reported an objective response rate (ORR) of 63.7% and an impressive disease control rate (DCR) of 94.5%. The study also highlighted median duration of response (DoR) and median progression-free survival (PFS) at 14.06 months and 14.55 months, respectively.
Impact on Patients with CNS Metastasis
A deeper analysis of 90 patients exhibiting CNS metastasis at the beginning of the study demonstrated an ORR of 55.6% and a DCR of 93.3%. Notably, median values for DoR and PFS were documented at 17.25 months, with median OS reaching 43.01 months.
Intracranial Responses and Safety Profile
The study applied RECIST v1.1 criteria, registering an 18.9% intracranial complete response (CR) among patients initially presenting with CNS metastasis. In the subgroup of 42 patients who had measurable intracranial lesions, an intracranial objective response rate (iORR) of 64.3% and an iDCR of 95.2% were reported.
On the safety front, the trial observed a high incidence of treatment-related adverse events (TRAEs) at 93.8%, with 30.8% of these classified as grade 3 or 4. Common TRAEs included elevations in aspartate aminotransferase, hypercholesterolemia, and increased alanine aminotransferase levels. Importantly, no new safety signals emerged during this study.
Long-term Benefits of Iruplinalkib
The long-term follow-up from the INTELLECT trial underlined that iruplinalkib offers significant OS benefits for patients with advanced NSCLC resistant to crizotinib while maintaining a robust safety profile.
Frequently Asked Questions
What is iruplinalkib?
Iruplinalkib is a next-generation ALK/ROS1 kinase inhibitor developed specifically for treating ALK-positive non-small-cell lung cancer.
What were the key findings from the Phase II clinical trial?
The trial reported a median overall survival of 41.79 months with high objective response and disease control rates, along with a manageable safety profile.
Who led the INTELLECT study?
The study was led by Prof. Yuankai Shi from the Cancer Hospital of the Chinese Academy of Medical Sciences & Peking Union Medical College.
Is iruplinalkib approved for use?
Yes, iruplinalkib has received approval from the NMPA for treating patients with advanced ALK-positive NSCLC.
What are treatment-related adverse events associated with iruplinalkib?
Common adverse events include elevated liver enzymes and hypercholesterolemia, but no new safety signals have been detected during the study.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Klarna and UATP Team Up for Growth in Air Travel Payments
- Boomi Celebrates Recognition as Top Workplace for Innovators
- Smartkem Partners with Chip Foundation to Transform MicroLED Tech
- FIS Unveils Exciting Fintech Innovations for 2024 Accelerator
- Organizations Recognize AI's Role in Transforming Customer Experience
- RecNation Expands Operations with New Location in California
- SquareWorks Consulting Unveils New Automation Feature for Finance
- Dynagas LNG Partners LP Delivers Strong Q2 2024 Performance
- FranklinCovey and WOBI Join Forces for Global Leadership Events
- Oracle and RAFAEL Team Up for Cloud-Powered Defense Solutions
Recent Articles
- Barclays Invests $26 Million in Versana's Future Growth
- Terry Dunlap Joins NetRise to Elevate Cybersecurity Strategy
- Michael Martin Joins TradingBlock as VP of Market Strategy
- RevHealth Strengthens Leadership with Key Executive Appointments
- Smarsh Team Releases Major Textbook on Language Models
- Bluntd Cones Partners with ActionPac to Innovate Pre-rolls
- KBR Enhances Support for Australia's Naval Submarine Program
- Stellus Capital Management Drives Growth for B&A Partners
- Innovative Wet Paint Options from meviy Transform Sheet Metal Coatings
- Proprio Celebrates 50 Surgeries with AI-Powered Surgical Platform
- Wigand Integrated Wealth Launches Innovative Tax Services
- mesur.io Earns Top Innovator Title in Global Sustainability Challenge
- Leveraging Volume Price Analysis for Market Predictions
- Strategic Risk Management for Today’s Market Environment
- Mattermost Welcomes Pavel Zeman as New Engineering Leader
- Sfil Unveils Impressive 2024 Interim Financial Performance
- Unlocking Wealth: Strategies for Crypto Success in 2024
- Exploring the Growth of Magnesium Chloride Market by 2032
- Innovative Wi-Fi 7 RF Solutions from Tower Semiconductor
- Inception Growth Acquisition Limited Extends Business Combination Period
- Exploring the Surge of the Automotive E-Compressor Market
- CTERA and MTI Enhance Collaboration for Digital Solutions
- Surging Growth of Drone Photography Services Market by 2034
- Alternative Protein Market Predicted to Exceed $31 Billion Soon
- Growth Projections for Antifog Additives Market in Future
- Anticipated Growth of Global Genetic Engineering Market to USD 8.95B
- High Electron Mobility Transistor Market Poised for Growth
- S64 Expands Operations in Asia with New Head for South Korea
- Navigating Legal Challenges: Outset Medical Shareholder Update
- Innovative Bitcoin Mining Taps Renewable Energy Potential
- Investors Should Connect with Legal Experts Regarding Lululemon
- Class Action Lawsuit Against ZoomInfo Technologies Inc. Unfolds
- Class Action Seeks Investor Recovery Against DXC Technology
- Investors Stand Up Against Sage Therapeutics' Alleged Deceptions
- CAE Inc. Faces Class Action Lawsuit Over Securities Issues
- CVS Health Corporation Shareholders Urged to Join Lawsuit
- Understanding Class Action Lawsuits for Verve Therapeutics Investors
- Levi & Korsinsky Urges Vicor Shareholders to Act Swiftly
- Investors Alert for Moderna: Class Action Lawsuit Announced
- Key Insights for American Airlines Investors: Know Your Rights
- Walgreens Investors Alert: Class Action Lawsuit Details Inside!
- Join the Class Action for Orthofix Medical Inc. Investors
- Join the Class Action Against Orthofix Medical Inc. Today
- Endava plc Faces Class Action Lawsuit Over Business Practices
- Investors Urged to Act Following MacroGenics Class Action Update
- Learn How Sprinklr, Inc. Investors Can Protect Their Rights
- GitLab Faces Securities Fraud Lawsuit: Key Details for Investors
- Methode Electronics Investors: Class Action Lawsuit Insights
- HepaTx Partners with Mayo Clinic to Innovate Liver Disease Therapies
- Apple's Hearing Aid Feature Shakes Up the Market Dynamics